𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women

✍ Scribed by Tair Kontorovich; Asaf Levy; Michael Korostishevsky; Uri Nir; Eitan Friedman


Publisher
John Wiley and Sons
Year
2010
Tongue
French
Weight
530 KB
Volume
127
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

We hypothesized that aberrant gene silencing by miRNA may affect mutant BRCA penetrance. To test this notion, frequency of single nucleotide polymorphisms (SNPs; n = 42) within predicted miRNA binding sites or miRNA precursors were determined and compared in 363 BRCA1 mutation carriers: asymptomatic (n = 160), breast cancer (n = 140) and ovarian cancer (n = 63) patients, and in 125 BRCA2 mutation carriers: asymptomatic (n = 48), breast cancer (n = 58) and ovarian cancer (n = 19) patients. Overall, 16 of 42 SNPs were polymorphic, 11 had a minor allele frequency greater than 5% and 9 of them maintained the Hardy‐Weinberg Equilibrium. Based on Cox regression and Kaplan–Meier analyses, statistically significant differences were noted in BRCA2 mutation carriers by health status in 3 SNPs: CC homozygosity at rs6505162 increased ovarian cancer risk (RR 2.77; p = 0.028; 95% CI, 1.11–6.9); heterozygote SNP carriers of rs11169571 had an ∼2 fold increased risk for developing breast/ovarian cancer, whereas heterozygotes of the rs895819 SNP had an ∼50% reduced risk for developing breast/ovarian cancer. This study provides preliminary evidence for another regulatory level of penetrance of deleterious mutations in cancer predisposition genes.


📜 SIMILAR VOLUMES


Single-nucleotide polymorphisms in the p
✍ Ronit I. Yarden; Eitan Friedman; Sally Metsuyanim; Tzvia Olender; Edna Ben-Asher 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 367 KB

## Abstract Germline mutations in the BRCA1 and BRCA2 genes are associated with a significantly increased lifetime risk for developing breast and/or ovarian cancer. However, incomplete penetrance and substantial variability in age of disease onset among carriers of the same mutation suggests the in